Andrew Booth - Nov 11, 2021 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role: Chief Financial Officer
Signature: /s/ Tryn Stimart, attorney-in-fact
Stock symbol: ABCL
Transactions as of: Nov 11, 2021
Transactions value $: $993,130
Form type: 4
Date filed: 11/15/2021, 05:05 AM
Previous filing: Jun 10, 2021
Next filing: Dec 9, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABCL	Common Shares	Purchase	$789K	+53.5K		$14.74	53.5K	Nov 11, 2021	Direct	F1
transaction	ABCL	Common Shares	Purchase	$205K	+14K	+11.97%	$14.61	131K	Nov 11, 2021	By spouse	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted-average price. These shares were sold in two transactions at prices $14.60 and $14.67. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in two transactions at prices $14.67 and $14.75. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted-average price. These shares were sold in two transactions at prices $14.60 and $14.67. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted-average price. These shares were sold in two transactions at prices $14.67 and $14.75. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.